Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Short Interest Down 18.9% in November

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 4,590,000 shares, a decline of 18.9% from the October 31st total of 5,660,000 shares. Based on an average daily volume of 2,490,000 shares, the short-interest ratio is presently 1.8 days.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRNS shares. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research report on Monday, September 23rd. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Finally, LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Nine analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS traded down $0.00 during trading hours on Friday, hitting $0.32. The stock had a trading volume of 401,285 shares, compared to its average volume of 1,555,463. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The stock has a market capitalization of $17.91 million, a price-to-earnings ratio of -0.13 and a beta of 1.26. The company’s fifty day moving average is $0.98 and its two-hundred day moving average is $1.24.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MRNS. Hussman Strategic Advisors Inc. increased its holdings in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at $28,000. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals in the second quarter valued at about $34,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.